Actively Recruiting
Safety and Efficacy of Anakinra for Acute Ischemic Stroke After Endovascular Treatment Comparing Different Doses with Standard Care
Led by Beijing Tiantan Hospital · Updated on 2026-10-16
159
Participants Needed
6
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of different doses of Anakinra compared to standard medical care in adults who have had an acute ischemic stroke and successful recanalization through endovascular thrombectomy. This phase 2, multicenter, randomized, open-label trial focuses on patients with stroke caused by blockage in key arteries confirmed by imaging, with a specific range of stroke severity scores. Participants will be randomly assigned to one of three groups high-dose Anakinra with a loading dose followed by continuous infusion, low-dose Anakinra with a loading dose followed by twice-daily injections, or standard medical treatment as per guidelines. Treatments begin within 30 minutes after randomization, and standard care is provided alongside the investigational interventions. Throughout the study, participants will undergo MRI scans to measure changes in brain injury size within 5 to 7 days. Additional assessments include neurological scales at various time points, evaluation of functional outcomes at 90 days, and monitoring for safety events. The total study duration includes treatment and follow-up periods, with the primary focus on reducing stroke damage and improving recovery.
CONDITIONS
Brief Title
Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
Research Team
Y
Yunyun Xiong, professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here